U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839235) titled 'Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)' on Feb. 17.
Brief Summary: The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long...